Observational Study of Efgartigimod Alfa for Myasthenia Gravis
This is an observational study looking at the long-term safety of efgartigimod alfa in people with generalized myasthenia gravis (gMG), a condition causing muscle weakness. The study will compare patients taking efgartigimod alfa to those not taking it. Researchers are especially interested in serious infections. You can join if you are 18 or older, have gMG, and are either starting efgartigimod alfa, are in your first cycle of treatment, or are not taking efgartigimod alfa. The study aims to follow participants for up to 10 years. The current status of this study is unclear.
- Study design
- This is an observational study with a planned enrollment of 680 participants. It compares patients taking efgartigimod alfa to those not taking it.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 10 years to assess the long-term safety of efgartigimod alfa.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
At a glance
Conditions
Where it's being run
35 sites across 17 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- The overall long-term safety of efgartigimod including the occurrence of serious infections in generalized myasthenia gravis (gMG) patients treated with efgartigimod compared to gMG patients not exposed to efgartigimodup to 10 years